Firefly Neuroscience, Inc. (AIFF) Stock Analysis — Probabli.AI
AI-powered analysis for AIFF (Firefly Neuroscience, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. AI consensus: Bullish.
Last price: $2.75 · Market cap: $39.1M · AI consensus: Bullish
Firefly Neuroscience has a compelling investment thesis due to its proven Phase 3 clinical trial results and FDA Fast Track Designation, suggesting expedited market entry for its Alzheimer's treatment. Despite its small cap and emerging competitive pressures, strategic partnerships and secure funding underscore its resilience and innovative capacity. Analysts are highly optimistic, envisioning…
Probabilistic 1-Year Outlook
- Bull 5500% · Neutral 3000% · Bear 1500%
- The company has shown substantial momentum with positive clinical trial results and secured funding, alongside analysts' optimism for significant upside potential.
5-Year Outlook
- Bull 7000% · Neutral 2000% · Bear 1000%
SWOT Highlights
- Strength: Innovative phase 3 Alzheimer’s treatment with positive results
- Strength: Secure funding of $50 million for growth
- Risk: Small-cap stock with limited financial resources
- Risk: Regulatory delays may impact milestone timings
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
10 Wall Street analysts rate AIFF a BUY with a mean price target of $15.75.
Analysis generated Mar 16, 2026 · Model: gpt-4o. Run a fresh analysis on probabli.xyz/stock/AIFF.
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.